XML 195 R37.htm IDEA: XBRL DOCUMENT
v3.20.4

Disposition of the Hospital Business - (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract] |
Disposal Groups, Including Discontinued Operations | The $45,760 gain represents the aggregate consideration of $42,000, less transaction fees of $2,928, plus the assets and liabilities either transferred to the Exela Buyer or eliminated by us due to the sale of the Hospital Products, which are listed below.
|  | December 31, 2020
Prepaid expenses and other current assets |  | $ | (134) |
Inventories |  | (4,922) |
Goodwill |  | (1,654) |
Intangible assets, net |  | (407) |
Other non-current assets |  | (1,095) |
Total long-term contingent consideration payable |  | 14,900 |
Net liabilities disposed of |  | 6,688 |
Aggregate consideration |  | 42,000 |
Less transaction fees |  | (2,928) |
Net gain on the sale of the Hospital Products |  | $ | 45,760 |
Schedule of Error Corrections and Prior Period Adjustments | The pro forma adjustments are based on available information and assumptions that the Company believes are attributable to the sale.
|  | Unaudited Pro Forma Condensed Combined Balance Sheet
|  | As of December 31, 2019
|  | As Reported |  | Pro Forma Adjustments |  | Notes |  | Pro Forma
ASSETS |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 9,774 |  |  | $ | 12,935 |  |  | (a) |  | $ | 22,709 |
Inventories |  | 3,570 |  |  | (3,570) |  |  | (b) |  | — |
Prepaid expenses and other current assets |  | 4,264 |  |  | 27,500 |  |  | (c) |  | 31,764 |
Goodwill |  | 18,491 |  |  | (1,654) |  |  | (d) |  | 16,837 |
Intangible assets, net |  | 813 |  |  | (813) |  |  | (e) |  | — |
Other non-current assets |  | 39,274 |  |  | (9,702) |  |  | (f) |  | 29,572 |
Total assets |  | $ | 151,436 |  |  | $ | 24,696 |  |  |  |  | $ | 176,132 |
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) |  |  |  |  |  |  |  |
Current portion of long-term contingent consideration payable |  | $ | 5,554 |  |  | $ | (5,054) |  |  | (g) |  | $ | 500 |
Accrued expenses |  | 19,810 |  |  | 2,800 |  |  | (h) |  | 22,610 |
Long-term contingent consideration payable, less current portion |  | 11,773 |  |  | (11,773) |  |  | (g) |  | — |
Total liabilities |  | 180,635 |  |  | (14,027) |  |  |  |  | 166,608 |
Shareholders’ equity (deficit): |  |  |  |  |  |  |  |
Accumulated deficit |  | (391,215) |  |  | 38,723 |  |  | (i) |  | (352,492) |
Total shareholders’ (deficit) equity |  | (29,199) |  |  | 38,723 |  |  |  |  | 9,524 |
Total liabilities and shareholders’ equity (deficit) |  | $ | 151,436 |  |  | $ | 24,696 |  |  |  |  | $ | 176,132 |
Adjustments to the pro forma unaudited condensed combined balance sheet (a) This adjustment represents the receipt of $14,500 cash consideration from the Exela Buyer at the closing of the Transaction less $1,565 placed into escrow for the estimated earn outs and royalties payable to Breaking Stick Holdings L.L.C., Horizon Santé FLML, Sarl, Deerfield Private Design Fund II, L.P., all affiliates of Deerfield Capital L.P. ("Deerfield") and Broadfin Healthcare Master Fund ("Broadfin") for the current year ended. (b) This adjustment reflects the elimination of Inventories that were purchased as part of the Transaction. (c) This adjustment reflects the Transaction consideration in the form of ten monthly installment payments of $2,750 (totaling $27,500) beginning 90 days from the Closing date. (d) This adjustment reflects the elimination of $1,654 of Goodwill based on the relative fair value of the Hospital Products as a portion of the overall value of the Company. (e) This adjustment reflects the elimination of the unamortized balance of the Intangible asset on acquired developed technology for Vazculep. (f) This adjustment reflects the elimination of $1,228 of other long-term assets and $8,474 of deferred tax assets at December 31, 2019. The eliminated deferred tax assets are tax attributes of the Hospital Products. (g) This adjustment reflects the elimination of short and long term related party payables, less the expected amounts due to Deerfield and Broadfin after taking into consideration the escrow discussed in Note (a). As part of the Transaction, the buyer agreed to assume the quarterly earn-out and royalty payments for periods after the close of the Transaction. The Company will no longer be responsible for these payments. (h) This adjustment reflects the estimated transaction fees payable related to the Transaction. (i) This adjustment reflects the estimated gain of $38,723 arising from the Transaction for the year ended December 31, 2019. This estimated gain has not been reflected in the pro forma unaudited condensed combined statements of loss as it is considered to be nonrecurring in nature. No adjustment has been made to the sale proceeds to give effect to any potential post-closing adjustments under the terms of the Purchase Agreement.
|  | Unaudited Pro Forma Condensed Combined Statement of Income (Loss)
|  | Year Ended December 31, 2020
|  | As Reported |  | Pro Forma Adjustments |  | Notes |  | Pro Forma
Product sales |  | $ | 22,334 |  |  | $ | (22,175) |  |  | (j) |  | $ | 159 |
Total operating expense |  | 16,519 |  |  | (8,392) |  |  | (k) |  | 8,127 |
Operating income (loss) |  | 5,815 |  |  | (13,783) |  |  |  |  | (7,968) |
Loss before income taxes |  | $ | (5,082) |  |  | $ | (13,348) |  |  | (l) |  | $ | (18,430) |
|  | Unaudited Pro Forma Condensed Combined Statement of Income (Loss)
|  | Year Ended December 31, 2019
|  | As Reported |  | Pro Forma Adjustments |  | Notes |  | Pro Forma
Product sales |  | $ | 59,215 |  |  | $ | (59,273) |  |  | (j) |  | $ | (58) |
Total operating expense |  | 83,327 |  |  | (16,092) |  |  | (m) |  | 67,235 |
Operating income (loss) |  | (24,112) |  |  | (43,181) |  |  |  |  | (67,293) |
Loss before income taxes |  | $ | (38,582) |  |  | $ | (42,803) |  |  | (n) |  | $ | (81,385) |
Adjustments to the pro forma unaudited condensed combined statements of income (loss) (j) This adjustment reflects Product sales attributable to the Hospital Products. (k) This adjustment reflects the following estimated expenses attributable to the Hospital Products: •Cost of products of $3,540. •R&D expenses of $322. •Selling, general and administrative expenses of $797. •Intangible asset amortization on acquired development technology for Vazculep of $406. •Changes in fair value of related party contingent consideration of $3,327. The Company will no longer be responsible for these payments. (l) This amount reflects the adjustments noted in (j) and (k) above, as well as estimated Changes in fair value of related party payable of $435 attributable to the Hospital Products. The Company will no longer be responsible for these payments. (m) This adjustment reflects the following estimated expenses attributable to the Hospital Products: •Cost of products of $11,368. •R&D expenses of $1,960. •Selling, general and administrative expenses of $1,102. •Intangible asset amortization on acquired development technology for Vazculep of $816. •Changes in fair value of related party contingent consideration of $845. The Company will no longer be responsible for these payments. (n) This amount reflects the adjustments noted in (j) and (m) above, as well as the reversal of estimated Changes in fair value of related party payable of $378 attributable to the Hospital Products. The Company will no longer be responsible for these payments.

X
- References No definition available. + Details
Name: | us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3A -URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5D -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3A -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 4B -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5C -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5A -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760 Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 4A -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760 + Details
Name: | us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details
Name: | us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration